Dr. Ullman is CEO of Stratosvir, a company engineering next generation viral immunotherapies to treat solid tumours and metastases, funded by CRUK and DSV. His background is virology, molecular biology and protein engineering. He was Team Leader at Gendaq Ltd (acquired by Sangamo Biosciences Inc), a spin-out from Nobel prize-winner’s Sir Aaron Klug’s lab at the LMB that engineered gene regulation. He joined Isogenica, coinvented CIS display for molecular evolution, becoming CSO and CEO, and commercialised new methods and designs for novel peptide and antibody fragment libraries. After Isogenica, as an independent consultant, he advised clients in antibody engineering and biological drug discovery, including nanoparticle and small molecule delivery systems for cancer therapy. He cofounded Stratosvir with Dr. Antonio Postigo to overcome the barriers for viruses to be used more widely in the treatment of cancer.